Biology behind new drug used to treat triple-negative breast cancer uncovered

How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center who worked in collaboration with scientists at the University of Miami, Florida. The finding appeared July 13, 2023, in Nature Breast Cancer.